Invesaro

Stocks Comparison

Gilead Sciences vs Moderna: revenue, profit, margins and growth compared

Gilead Sciences brought in $29.4B of revenue in fiscal 2025, Moderna $1.9B in fiscal 2025. Revenue changed by +2.4% at Gilead Sciences and -39.9% at Moderna on the year before, so Gilead Sciences grew faster. Gilead Sciences kept 28.9% of its revenue as net profit, Moderna -145.2%. Free cash flow was $9.5B at Gilead Sciences and -$2.1B at Moderna.

Side by side, latest fiscal year

GILDMRNA
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$29.4B$1.9B
Revenue growth+2.4%-39.9%
Net income$8.5B-$2.8B
Net margin28.9%-145.2%
Free cash flow$9.5B-$2.1B
Free cash flow margin32.1%-106.2%
Earnings per share (diluted)$6.78-$7.26
Cash$7.6B$2.6B
Debt$24.9B$590M
Price to earnings22.3n/a
Market value$187.1B$79.4B
Dividend yield2.09%n/a
Rank by revenue in sector#22 of 523 · Health care#111 of 523 · Health care

Over the years

Revenue
GILD FY2018: $22.1BGILD FY2019: $22.4BGILD FY2020: $24.7BGILD FY2021: $27.3BGILD FY2022: $27.3BGILD FY2023: $27.1BGILD FY2024: $28.8BGILD FY2025: $29.4BMRNA FY2018: $135.1MMRNA FY2019: $60.2MMRNA FY2020: $803MMRNA FY2021: $18.5BMRNA FY2022: $19.3BMRNA FY2023: $6.8BMRNA FY2024: $3.2BMRNA FY2025: $1.9BFY18FY19FY20FY21FY22FY23FY24FY25
GILD $29.4BMRNA $1.9B
Net income
GILD FY2018: $5.5BGILD FY2019: $5.4BGILD FY2020: $123MGILD FY2021: $6.2BGILD FY2022: $4.6BGILD FY2023: $5.7BGILD FY2024: $480MGILD FY2025: $8.5BMRNA FY2018: -$384.7MMRNA FY2019: -$514MMRNA FY2020: -$747MMRNA FY2021: $12.2BMRNA FY2022: $8.4BMRNA FY2023: -$4.7BMRNA FY2024: -$3.6BMRNA FY2025: -$2.8BFY18FY19FY20FY21FY22FY23FY24FY25
GILD $8.5BMRNA -$2.8B
Net margin
GILD FY2018: 24.7%GILD FY2019: 24.0%GILD FY2020: 0.5%GILD FY2021: 22.8%GILD FY2022: 16.8%GILD FY2023: 20.9%GILD FY2024: 1.7%GILD FY2025: 28.9%MRNA FY2018: -284.8%MRNA FY2019: -853.7%MRNA FY2020: -93.0%MRNA FY2021: 66.1%MRNA FY2022: 43.4%MRNA FY2023: -68.8%MRNA FY2024: -110.0%MRNA FY2025: -145.2%FY18FY19FY20FY21FY22FY23FY24FY25
GILD 28.9%MRNA -145.2%
Revenue growth
GILD FY2019: +1.5%GILD FY2020: +10.0%GILD FY2021: +10.6%GILD FY2022: -0.1%GILD FY2023: -0.6%GILD FY2024: +6.0%GILD FY2025: +2.4%MRNA FY2019: -55.4%MRNA FY2020: +1,233.7%MRNA FY2021: +2,200.2%MRNA FY2022: +4.3%MRNA FY2023: -64.4%MRNA FY2024: -52.7%MRNA FY2025: -39.9%FY19FY20FY21FY22FY23FY24FY25
GILD +2.4%MRNA -39.9%
Free cash flow
GILD FY2018: $7.5BGILD FY2019: $8.3BGILD FY2020: $7.5BGILD FY2021: $10.8BGILD FY2022: $8.3BGILD FY2023: $7.4BGILD FY2024: $10.3BGILD FY2025: $9.5BMRNA FY2018: -$436.6MMRNA FY2019: -$491MMRNA FY2020: $2BMRNA FY2021: $13.3BMRNA FY2022: $4.6BMRNA FY2023: -$3.8BMRNA FY2024: -$4.1BMRNA FY2025: -$2.1BFY18FY19FY20FY21FY22FY23FY24FY25
GILD $9.5BMRNA -$2.1B

Fiscal years as each company reports them; the two may end in different months.

Questions about Gilead Sciences and Moderna

Which is bigger by revenue, Gilead Sciences or Moderna?

Gilead Sciences is bigger by revenue: $29.4B in fiscal 2025, against $1.9B for Moderna in fiscal 2025.

Which keeps more of its revenue as profit, Gilead Sciences or Moderna?

Gilead Sciences had a net margin of 28.9% in fiscal 2025; Moderna had -145.2% in fiscal 2025.

Which grew revenue faster, Gilead Sciences or Moderna?

In their latest fiscal years revenue changed by +2.4% at Gilead Sciences and -39.9% at Moderna.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies